Founded December 2011
Investors Trendlines Incubators Israel; private investors in Israel, United States, Europe and Singapore; founders
CEO Ohad Schwartz
CoreBone has developed, and is distributing, bioactive, coral-based bone graft material that provides a natural alternative to human and animal-derived (bovine, porcine) bone graft material for dental and orthopedic indications, providing a natural alternative to human and animal derived materials.
CoreBones patented technology embeds bioactive minerals (e.g., silicium) into the skeleton of corals during their growth process to accelerate healing and provide better connectivity. The CoreBone graft offers the same bonelike qualities as organic material (human/animal derived) without the associated risks.
CEO Ohad Schwartz appears on Start-Up Stadium (Hebrew).
CoreBone's Ohad Schwartz interviewed on ILTV.
CoreBone corals are grown in a closed, controlled aquatic (aquarium) system.
Former CEO, Vaica Medical (medication management); CEO and co-founder, Aspect AI (MRI technologies); VP, TAMI 4
Internationally recognized researcher in bone biology and dentistry; former head of Dental Dept. and Hard Tissue Laboratory, Sourasky Medical Center, Tel Aviv; School of Dental Medicine and Dept. of Bioengineering, Tel Aviv Univ.; senior researcher, Hospital for Special Surgery, New York
Today, implants are used more and more in dental and orthopedics. In many cases, bone is insufficient, and bone grafts stimulate the growth of new bone to support and anchor the implant. Most bone graft materials in the market are derived from human and animal bone and carry the risk of disease and rejection. *Furthermore, bovine-derived products hardly remodel due to the heat treatment that is essential to reduce viral risks. Synthetic materials, a fast-growing segment, lack strength.
Bone grafts from human and animal origin are in decline due to their associated risks. The synthetic bioactive product share is growing as the market seeks alternatives. The global market for orthopedic bone graft substitutes is expected to reach $3.4 billion by 2022 (Allied Market Research). According to Transparency Market Research, the global dental membrane and bone graft substitutes market is expected to reach $922.6 million by 2024.